We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Applied DNA Sciences Inc | NASDAQ:APDN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.37 | -9.05% | 3.72 | 3.72 | 3.82 | 4.75 | 3.59 | 4.09 | 146,279 | 23:53:08 |
For the years ended September 30, 2011 and 2010, the company generated $968,848 and $519,844 in revenues from operations, respectively. The 86% increase in revenues was substantially generated from sales of our SigNature DNA and BioMaterial GenoTyping products. We were able to increase our customer base by 40% in fiscal 2011 aided by our expanded sales team this year.
Selling, general and administrative expenses for the twelve months ended September 30, 2011 increased 16.69% to $8,388,873 from $7,189,020 in the same period in 2010. Included within the selling, general and administrative expenses for the year ended September 30, 2011 was a noncash charge to operations of $3,668,460 for the fair value of vested options issued to officers and employees and other stock based compensation compared to $3,796,255 in 2010.
Research and development expenses increased by $192,915 for the twelve months ended September 30, 2011 primarily due to an increase in research and development activities to support our increased customer demand.
Total operating expenses increased to $9,025,305 for the twelve months ended September 30, 2011 from $7,636,895, or an increase of $1,388,410, primarily due to increase in professional and other service providers expenses compared to the for the same period last year.
Net loss for the twelve months ended September 30, 2011 was $10,515,124 compared to $7,909,600 in the same period of 2010, a net change of $ 2,605,524 as a result of the combination of factors described above.
Key 2011 achievements include:
"While this is our best year yet, we are just beginning to see the fruits of our labor. The company is at a critical juncture in its development, its reputation and relationships expanding continuously. We are grateful for the continued support of our customers, strategic partners, employees and investors this year. We have made significant progress toward our goals and we believe our vision and strategy will take us there," commented Dr. James Hayward, President and CEO of APDN.
The annual report on Form 10-K, which includes Applied DNA Sciences audited consolidated financial statements, is available for viewing and downloading, free of charge, through the Investor Relations section of APDN's Web site at www.adnas.com, or through the SEC's electronic data system at www.sec.gov.
About APDN APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. Our mark provides a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to www.adnas.com where APDN routinely posts all press releases.
The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
Add to Digg Bookmark with del.icio.us Add to Newsvine
INVESTOR CONTACT: Debbie Bailey 631-444-8090 fax: 631-444-8848 MEDIA CONTACT: Mitchell Miller Email Contact FCMN Contact: Email Contact Web site: http://www.adnas.com Twitter: @APDN, @APDNInvestor
1 Year Applied DNA Sciences Chart |
1 Month Applied DNA Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions